PT2678679T - Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos - Google Patents

Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos

Info

Publication number
PT2678679T
PT2678679T PT127048262T PT12704826T PT2678679T PT 2678679 T PT2678679 T PT 2678679T PT 127048262 T PT127048262 T PT 127048262T PT 12704826 T PT12704826 T PT 12704826T PT 2678679 T PT2678679 T PT 2678679T
Authority
PT
Portugal
Prior art keywords
furazanobenzimidazoles
biomarker
drug response
acetylated tubulin
tubulin
Prior art date
Application number
PT127048262T
Other languages
English (en)
Inventor
Alexandra Lane Heidi
Bachmann Felix
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PT2678679T publication Critical patent/PT2678679T/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT127048262T 2011-02-24 2012-02-21 Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos PT2678679T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11155774 2011-02-24

Publications (1)

Publication Number Publication Date
PT2678679T true PT2678679T (pt) 2017-04-07

Family

ID=44065555

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127048262T PT2678679T (pt) 2011-02-24 2012-02-21 Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos

Country Status (13)

Country Link
US (2) US9476889B2 (pt)
EP (1) EP2678679B1 (pt)
JP (1) JP6295081B2 (pt)
CN (1) CN103392130B (pt)
AU (1) AU2012219611C1 (pt)
CA (1) CA2824497A1 (pt)
DK (1) DK2678679T3 (pt)
ES (1) ES2621413T3 (pt)
HU (1) HUE032187T2 (pt)
PL (1) PL2678679T3 (pt)
PT (1) PT2678679T (pt)
WO (1) WO2012113802A1 (pt)
ZA (1) ZA201306086B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10006078B2 (en) * 2011-03-29 2018-06-26 Basilea Pharmaceutica Ag Use of phospho-Akt as a biomarker of drug response
US10392920B2 (en) * 2013-12-05 2019-08-27 Schlumberger Technology Corporation Method and system of quantitative cement evaluation using logging while drilling
US10578455B2 (en) * 2014-03-06 2020-03-03 Mitsubishi Heavy Industries, Ltd. Device for providing electric-moving-body information and method for providing electric-moving-body information
EP3365680A1 (en) 2015-10-22 2018-08-29 Basilea Pharmaceutica International AG Use of eb1 as a biomarker of drug response
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
WO2018210868A1 (en) 2017-05-16 2018-11-22 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
WO2019097073A1 (en) * 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN109053584B (zh) * 2018-09-12 2022-03-18 南京大学 一类1,2-二芳基苯并咪唑衍生物的制备及其应用
EP3853224A1 (en) * 2018-09-20 2021-07-28 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
KR102503593B1 (ko) * 2020-03-11 2023-02-24 연세대학교 산학협력단 항암제 내성 진단 또는 치료용 조성물
WO2021186855A1 (ja) * 2020-03-16 2021-09-23 株式会社マンダム T細胞性リンパ腫の指標の検出方法、及びその利用
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response
EP4551943A1 (en) * 2022-07-06 2025-05-14 I3S - Instituto de Investigação e Inovação em Saúde, Associação Tubulin acetylation and its associated post-translational modifications as biomarkers of response to treatment with taxol, taxanes and other microtubule stabilizing anti-cancer agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095953A1 (en) * 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
AU2002361022A1 (en) * 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
DK1636215T3 (da) 2003-05-23 2008-06-02 Basilea Pharmaceutica Ag Furazanobenzimidazoler
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
CA2679393A1 (en) * 2007-03-05 2008-09-12 Newsouth Innovations Pty Limited Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
CN101861151B (zh) * 2007-09-14 2014-08-13 梅特希尔基因公司 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗
NZ597376A (en) * 2009-07-27 2014-01-31 Basilea Pharmaceutica Ag Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Also Published As

Publication number Publication date
DK2678679T3 (en) 2017-04-24
JP2014511486A (ja) 2014-05-15
ZA201306086B (en) 2014-04-30
EP2678679A1 (en) 2014-01-01
PL2678679T3 (pl) 2017-07-31
CN103392130B (zh) 2015-11-25
HK1191096A1 (zh) 2014-07-18
US20170122934A1 (en) 2017-05-04
AU2012219611C1 (en) 2016-07-21
AU2012219611B2 (en) 2016-03-03
US9476889B2 (en) 2016-10-25
EP2678679B1 (en) 2017-02-08
AU2012219611A1 (en) 2013-07-25
ES2621413T3 (es) 2017-07-04
US10067120B2 (en) 2018-09-04
WO2012113802A1 (en) 2012-08-30
HUE032187T2 (en) 2017-09-28
NZ613022A (en) 2015-11-27
CA2824497A1 (en) 2012-08-30
JP6295081B2 (ja) 2018-03-14
CN103392130A (zh) 2013-11-13
US20140005237A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
ZA201306086B (en) Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
GB201104096D0 (en) Production of graphene
ZA201403995B (en) Stereoselective total synthesis of noribogaine
IL233081A0 (en) History of Betulin
GB201002606D0 (en) Production of fuels
ZA201306520B (en) Use of phospho-akt as a biomarker of drug response
PT2666014T (pt) Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos
SG2014002240A (en) Production of paraxylene
EP2776586A4 (en) BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS
EP2666016A1 (en) Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
GB201004096D0 (en) Production of polyhydroalkanoates
PT2666015T (pt) Utilização de estatmina como um biomarcador da resposta farmacológica a furazanobenzimidazolos
ZA201400248B (en) Synthesis of cleistainthin a and derivatives thereof
SG2014011639A (en) Measuring form changes of a substrate
GB2488866B (en) Use of GPS to detect repetitive motion
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
PL2465868T3 (pl) Ulepszenie produkcji lipidów
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
EP2791349A4 (en) SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID
ZA201207838B (en) Use of zirconium or of a zirconium-comprising mixture
GB201106098D0 (en) Production of fuels
TWM433471U (en) Assembly structure of gear
GB201110310D0 (en) Paperless point of sale
GB201103801D0 (en) Movement of aircraft